Delivery Order SPE2DB22D3301-SPE2DB25FZ1QF
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Entecavir 0.5 mg tablets in a 30-count configuration. This is a firm fixed price delivery order with a ceiling value of $2,640.56 and an ultimate completion date of September 24, 2025. The award is not set-aside and represents a competitive award to AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania. The contract will be performed at the...
- The Defense Logistics Agency awarded a $1,996.61 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Entecavir 0.5 mg tablets (30-count units). This is a firm fixed-price delivery order with an ultimate completion date of August 12, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, consistent with AmerisourceBergen's typical federal procurement profile....
- The Defense Logistics Agency awarded a delivery order valued at $1,774.43 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count packages) on August 18, 2025, with completion scheduled for August 19, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value pharmaceutical procurement executed under a non-set-aside designation. The award is performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order valued at $2,691.55 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count) with a firm fixed price contract type and an ultimate completion date of September 16, 2025. This non-set-aside, competitively awarded delivery order will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The order represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Entecavir 0.5 mg tablets (30-count) valued at $3,383.40 under a firm fixed-price contract. The award, issued on September 22, 2025, with an ultimate completion date of September 23, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 27, 2025, for the supply of Entecavir 0.5 mg tablets (30-count units) with a ceiling value of $3,232.48 and a firm fixed price. This is a non-set-aside competitive award with an ultimate completion date of June 30, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $2,516.79 delivery order to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count units) under a firm fixed price contract. The order was competitively awarded without set-aside designation and is scheduled for completion by June 5, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this delivery order from its corporate office location. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,439.79 to AmerisourceBergen Drug Corp for Entecavir 0.5 mg tablets (30-count packaging) with a completion date of June 20, 2025. This non-set-aside, competitively awarded contract reflects a firm fixed-price delivery order issued on June 18, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order valued at $1,202.28 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count) on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Entecavir 0.5 mg tablets (30-count packaging) with a ceiling value of $1,650.08 under a firm fixed price contract type. The award was made on August 18, 2025, with an ultimate completion date of August 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation. This delivery...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FZ1QFDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Entecavir 0.5 mg tablets (30-count units) with a ceiling value of $13,010.16. This is a firm fixed price delivery order with an ultimate completion date of September 26, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's demonstrated capability to fulfill federal medical supply needs through open competition, combined with its extensive portfolio of pharmaceutical product deliveries across multiple therapeutic domains, positions it as a key supplier within the DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.0k | 9/25/25 |